Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company that specializes in developing advanced therapies for patients suffering from kidney diseases and chronic metabolic disorders. This Irvine, California-based firm is notable for its robust portfolio of product candidates designed to target and resolve critical medical conditions that contribute to various kidney diseases.
At the core of Unicycive Therapeutics' research and development is a strong focus on unmet clinical needs. According to the National Kidney Foundation, around 37 million people in the United States are reportedly carrying chronic kidney disease. With such alarming figures, UNCY has positioned itself as a key player in the quest to enhance the current treatment landscape.
One of Unicycive Therapeutics’ lead product candidates is Renazorb, a novel phosphate binder for patients with end-stage kidney disease on dialysis. As excessive phosphate in the blood can have detrimental effects on patients with kidney disease, Renazorb is designed to control phosphate levels, thereby significantly reducing the risk associated with high phosphate conditions. This product is currently undergoing phase 2 clinical trials.
Another major product candidate developed by Unicycive Therapeutics is UNI-494, a novel drug meant for Acute Kidney Injury (AKI) and chronic kidney disease. UNI-494 is designed to attenuate renal injury and improve renal function, thereby providing much-needed relief to patients suffering from these conditions.
Aside from these, UNCY is also developing several other promising product candidates, which are in various stages of development, targeting different types of kidney diseases and metabolic disorders.
Overall, Unicycive Therapeutics, Inc. (UNCY) plays a pivotal role in the biotechnology industry through its innovative approach to addressing unmet needs in the kidney disease therapy landscape. With a highly experienced leadership team and world-class research and development expertise, the company is well-poised to contribute significantly in improving the treatment outcomes for millions of patients suffering from kidney diseases and chronic metabolic disorders. Committed to becoming a recognized leader in kidney disease therapeutics, UNCY continues its drive to bring cutting-edge, life-changing treatments to the market.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Unicycive Therapeutics reported US$59 million in cash and securities, which is expected to fund operations beyond 2027, including potential launch costs for its kidney drug, oxylanthanum carbonate (OLC). The FDA's target action date for OLC is March 25, 2027, following a resubmission due to prior manufacturing vendor deficiencies. The company is preparing for a potential commercial launch, incurring increased general and administrative expenses in the third quarter of 2026.
Unicycive Therapeutics Inc. (UNCY) filed an SEC Form 8-K detailing its Q3 2026 financial results, reporting $59M in cash and a runway beyond 2027, despite a widened net loss of $0.33/share. The FDA has accepted its Oxylanthanum Carbonate New Drug Application with a PDUFA date of March 25, 2027. The article also provides historical stock performance data following previous headlines and explains what a Form 8-K entails.

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a biotechnology company focused on kidney disease treatments, announced that its CEO, Shalabh Gupta, M.D., will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 2:30 p.m. ET. The presentation will be webcast live and archived on the company's website. Unicycive is developing oxylanthanum carbonate for hyperphosphatemia and UNI-494 for acute kidney injury.

Unicycive Therapeutics announced that its CEO, Shalabh Gupta, M.D., will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 2:30 p.m. ET. The biotechnology company is focused on developing therapies for kidney disease, with lead candidates for hyperphosphatemia and acute kidney injury. A webcast of the presentation will be available on the company's website.